ResQ-209 trial (M-CENK): what clinicians have said so far
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
- NCT06710288 ↗
- Recruiting
- ImmunityBio, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ResQ-209 (M-CENK plus nogapendekin alfa inbakicept (N-803) plus gemcitabine in recurrent platinum-resistant high-grade ovarian cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ResQ-209 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Gemcitabine; N-803; M-CENK
- Arms
- All subjects · Experimental
- Enrollment
- 20 (estimated)
- Primary outcomes
- Evaluate Progression Free Survival (PFS)
- Evaluate Overall Survival (OS)
- Evaluate Objective Response Rate (ORR)
- Evaluate Duration of Response (DOR)
- Evaluate Disease Control Rate (DCR)
- Evaluate the time to progression or death on the next line of treatment (PFS2) of participants receiving M-CENK adoptive cell therapy and N-803 in combination with gemcitabine.
- Evaluate the CA-125 response rate (RR) per Gynecologic Cancer Intergroup (GCIC) CA-125 criteria.
- Sponsor
- ImmunityBio, Inc.
- Start
- Nov 6, 2024
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06710288 · updated Jul 1, 2026